Medtronic plc (MDT) | Financial Analysis & Statements
Medtronic plc Large-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jul 2025Income Metrics
Revenue
8.6B
Gross Profit
5.6B
65.02%
Operating Income
1.5B
17.67%
Net Income
1.0B
12.21%
EPS (Diluted)
$0.81
Balance Sheet Metrics
Total Assets
91.7B
Total Liabilities
43.4B
Shareholders Equity
48.3B
Debt to Equity
0.90
Cash Flow Metrics
Operating Cash Flow
2.1B
Free Cash Flow
2.1B
Revenue & Profitability Trend
Quarter Income Flow
Jul 31, 2025
Annual Income Flow
2025
Medtronic plc Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 33.5B | 32.4B | 31.2B | 31.7B | 30.1B |
| Cost of Goods Sold | 11.6B | 11.2B | 10.7B | 10.1B | 10.5B |
| Gross Profit | 21.9B | 21.1B | 20.5B | 21.5B | 19.6B |
| Gross Margin % | 65.3% | 65.3% | 65.7% | 68.0% | 65.2% |
| Operating Expenses | |||||
| Research & Development | 2.7B | 2.7B | 2.7B | 2.7B | 2.5B |
| Selling, General & Administrative | 10.8B | 10.7B | 10.4B | 10.3B | 10.1B |
| Other Operating Expenses | -23.0M | 464.0M | -131.0M | 862.0M | 315.0M |
| Total Operating Expenses | 13.6B | 13.9B | 13.0B | 13.9B | 13.0B |
| Operating Income | 6.5B | 5.5B | 5.8B | 5.9B | 4.9B |
| Operating Margin % | 19.5% | 17.1% | 18.7% | 18.6% | 16.3% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | - | - |
| Interest Expense | 729.0M | 719.0M | 636.0M | 553.0M | 925.0M |
| Other Non-Operating Income | -182.0M | 37.0M | 170.0M | 163.0M | -75.0M |
| Pre-tax Income | 5.6B | 4.8B | 5.4B | 5.5B | 3.9B |
| Income Tax | 936.0M | 1.1B | 1.6B | 456.0M | 265.0M |
| Effective Tax Rate % | 16.6% | 23.4% | 29.5% | 8.3% | 6.8% |
| Net Income | 4.7B | 3.7B | 3.8B | 5.1B | 3.6B |
| Net Margin % | 14.0% | 11.4% | 12.1% | 16.0% | 12.1% |
| Key Metrics | |||||
| EBITDA | 9.8B | 8.6B | 9.0B | 8.9B | 7.9B |
| EPS (Basic) | $3.63 | $2.77 | $2.83 | $3.75 | $2.68 |
| EPS (Diluted) | $3.61 | $2.76 | $2.82 | $3.73 | $2.66 |
| Basic Shares Outstanding | 1285600000 | 1327700000 | 1329800000 | 1342400000 | 1344900000 |
| Diluted Shares Outstanding | 1285600000 | 1327700000 | 1329800000 | 1342400000 | 1344900000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Medtronic plc Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 2.2B | 1.3B | 1.5B | 3.7B | 3.6B |
| Short-term Investments | 6.7B | 6.7B | 6.4B | 6.9B | 7.2B |
| Accounts Receivable | 6.5B | 6.1B | 6.0B | 5.6B | 5.5B |
| Inventory | 5.5B | 5.2B | 5.3B | 4.6B | 4.3B |
| Other Current Assets | 2.9B | 2.6B | 2.4B | 2.3B | 2.0B |
| Total Current Assets | 23.8B | 21.9B | 21.7B | 23.1B | 22.5B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 7.2B | 6.4B | 6.7B | 6.5B | 6.3B |
| Goodwill | 95.1B | 95.2B | 97.7B | 96.6B | 101.7B |
| Intangible Assets | 11.7B | 13.2B | 14.8B | 15.6B | 17.7B |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 7.6B | 7.7B | 7.4B | 6.4B | 5.6B |
| Total Non-Current Assets | 67.9B | 68.0B | 69.3B | 67.9B | 70.5B |
| Total Assets | 91.7B | 90.0B | 90.9B | 91.0B | 93.1B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 2.4B | 2.4B | 2.7B | 2.3B | 2.1B |
| Short-term Debt | 2.9B | 1.1B | 20.0M | 3.7B | 11.0M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 1.0M | - | -1.0M | - | - |
| Total Current Liabilities | 12.9B | 10.8B | 9.1B | 12.4B | 8.5B |
| Non-Current Liabilities | |||||
| Long-term Debt | 25.6B | 23.9B | 24.3B | 20.4B | 26.4B |
| Deferred Tax Liabilities | 403.0M | 515.0M | 708.0M | 884.0M | 1.0B |
| Other Non-Current Liabilities | 1.8B | 1.4B | 1.7B | 1.4B | 1.8B |
| Total Non-Current Liabilities | 30.5B | 28.8B | 30.2B | 25.9B | 33.0B |
| Total Liabilities | 43.4B | 39.6B | 39.3B | 38.3B | 41.5B |
| Equity | |||||
| Common Stock | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | 31.5B | 30.4B | 30.4B | 30.2B | 28.6B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 48.3B | 50.4B | 51.7B | 52.7B | 51.6B |
| Key Metrics | |||||
| Total Debt | 28.5B | 25.0B | 24.4B | 24.1B | 26.4B |
| Working Capital | 10.9B | 11.1B | 12.6B | 10.7B | 14.0B |
Balance Sheet Composition
Medtronic plc Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 4.7B | 3.7B | 3.8B | 5.1B | 3.6B |
| Depreciation & Amortization | 2.9B | 2.6B | 2.7B | 2.7B | 2.7B |
| Stock-Based Compensation | 429.0M | 393.0M | 355.0M | 359.0M | 344.0M |
| Working Capital Changes | -1.3B | -875.0M | -1.7B | -1.1B | -1.2B |
| Operating Cash Flow | 6.7B | 5.9B | 5.2B | 6.6B | 5.3B |
| Investing Activities | |||||
| Capital Expenditures | -1.9B | -1.6B | -1.5B | -1.4B | -1.4B |
| Acquisitions | -98.0M | -211.0M | -1.9B | -91.0M | -994.0M |
| Investment Purchases | -8.2B | -7.7B | -7.5B | -9.9B | -11.8B |
| Investment Sales | 8.5B | 7.4B | 7.3B | 9.7B | 11.3B |
| Investing Cash Flow | -1.9B | -2.4B | -3.5B | -1.7B | -2.9B |
| Financing Activities | |||||
| Share Repurchases | -3.2B | -2.1B | -645.0M | -2.5B | -652.0M |
| Dividends Paid | -3.6B | -3.7B | -3.6B | -3.4B | -3.1B |
| Debt Issuance | 3.2B | 0 | 5.4B | 0 | 7.2B |
| Debt Repayment | -1.1B | 0 | -8.3B | -1.0M | -10.5B |
| Financing Cash Flow | -5.4B | -4.4B | -7.2B | -5.3B | -7.3B |
| Free Cash Flow | 5.2B | 5.2B | 4.6B | 6.0B | 4.9B |
| Net Change in Cash | -656.0M | -881.0M | -5.5B | -435.0M | -4.9B |
Cash Flow Trend
Medtronic plc Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
23.47
Forward P/E
13.86
Price to Book
2.20
Price to Sales
3.04
PEG Ratio
-1.98
Profitability Ratios
Profit Margin
13.00%
Operating Margin
20.01%
Return on Equity
9.39%
Return on Assets
4.57%
Financial Health
Current Ratio
2.54
Debt to Equity
57.06
Beta
0.76
Per Share Data
EPS (TTM)
$3.58
Book Value per Share
$38.17
Revenue per Share
$27.68
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| MDT | 107.6B | 23.47 | 2.20 | 9.39% | 13.00% | 57.06 |
| Abbott Laboratories | 160.7B | 25.97 | 3.09 | 12.36% | 13.90% | 26.79 |
| Stryker | 126.3B | 39.21 | 5.62 | 15.08% | 12.92% | 72.97 |
| Boston Scientific | 97.6B | 27.49 | 4.02 | 11.84% | 17.29% | 48.92 |
| Edwards Lifesciences | 48.5B | 46.49 | 4.73 | 10.38% | 17.39% | 6.82 |
| Dexcom | 23.8B | 30.03 | 8.63 | 34.50% | 17.94% | 50.85 |
Financial data is updated regularly. All figures are in the company's reporting currency.






